샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793664

세계의 경구 단백질 및 펩티드 시장

Oral Proteins and Peptides
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 278 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 경구 단백질 및 펩티드 시장은 2030년까지 20억 달러에 도달

2024년에 13억 달러로 추정되는 경구 단백질 및 펩티드 세계 시장은 분석 기간인 2024-2030년 CAGR 7.4%로 성장하여 2030년에는 20억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 칼시토닌 약제 유형은 CAGR 6.1%를 나타내고, 분석 기간 종료시에는 7억 6,250만 달러에 이를 것으로 예측됩니다. 인슐린 제제 유형의 성장률은 분석 기간중 CAGR 9.6%로 추정됩니다.

미국 시장은 3억 5,160만 달러로 추정, 중국은 CAGR11.3%로 성장 예측

미국의 경구 단백질 및 펩티드 시장은 2024년에 3억 5,160만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년간 CAGR 11.3%로 2030년까지 4억 1,190만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 3.8%와 7.0%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 4.9%를 나타낼 전망입니다.

세계의 경구 단백질 및 펩티드 시장 - 주요 동향과 촉진요인 정리

단백질과 펩티드의 경구 투여가 기술적으로 어려운 이유는 무엇인가?

단백질과 펩티드는 소화기관에서 본질적으로 안정성이 떨어지는 섬세한 생체 분자입니다. 경구 투여시 위 효소와 가혹한 pH 조건으로 인해 급속한 분해에 직면하고 분자 크기가 크고 친수성이 높아 장내 흡수가 제한됩니다. 이러한 장벽으로 인해 지금까지 치료용 단백질의 경구 투여는 제한되어 왔으며, 대부분 비경구 투여로 전환되어 왔습니다. 그러나 최근 과학의 발전으로 경구 전달이 더욱 확실해지면서 펩티드 기반 경구용 의약품 개발에 대한 새로운 투자가 이루어지고 있습니다.

경구 투여의 동기가 강하고, 특히 당뇨병, 성장 장애, 호르몬 결핍증과 같은 장기적인 치료에 효과적입니다. 환자들은 편의성, 편안함, 주사와 관련된 합병증 위험 감소로 인해 주사보다 경구 요법을 선호합니다. 따라서 제약업계는 펩티드 구조를 안정화시키고 전신 흡수를 위해 점막 수송을 촉진하는 접근법을 적극적으로 연구하고 있습니다.

어떤 제형 기술이 소화관을 통한 전신 흡수를 가능하게 하는가?

펩티드와 단백질의 경구 전달을 가능하게 하기 위해 여러 제제화 전략이 활발히 개발되고 있습니다. 장용성 코팅 캡슐이나 효소 억제제를 사용하면 약물이 장에 도달할 때까지 보호하는 데 도움이 됩니다. 중쇄 지방산이나 담즙산과 같은 흡수 촉진제는 장 내벽의 단단한 접합부를 느슨하게 하고 일시적으로 투과성을 높이기 위해 사용됩니다. 나노입자, 자기유화형 약물전달시스템(SEDDS), 지질 기반 제제 등의 캐리어 시스템은 약물의 용해도와 안정성을 개선하기 위해 고안된 시스템입니다.

침투성을 높이는 마이크로 용기, 접착 필름, 경세포 수송기 등의 기술은 안정적이고 안전한 흡수를 달성하기 위해 개선되고 있습니다. 고리화 및 D-아미노산 치환을 포함한 펩티드의 구조적 변형은 생물학적 활성에 영향을 미치지 않고 효소 절단에 대한 내성을 향상시킵니다. 이러한 방법을 통해 더 많은 펩티드 의약품이 치료 효과에 충분한 생체 이용률 수준을 달성할 수 있게 되었습니다.

어떤 치료제가 개발을 주도하고, 혁신은 어디에 집중되어 있는가?

당뇨병과 대사성 질환은 경구용 펩티드 개발의 주요 치료 분야입니다. 2형 당뇨병 치료제인 경구용 GLP-1 수용체 작용제인 세마글루타이드는 가장 주목할 만한 상업적 성공 사례로, 이 분야에서 획기적인 발전을 이루었습니다. 골다공증 및 갑상선 관련 질환에 대한 인슐린, 부갑상선 호르몬, 칼시토닌의 경구용 제제를 타겟으로 한 노력도 마찬가지다.

바이오제약 기업들도 류마티스 관절염, 궤양성 대장염 등의 질환에 대한 펩티드 기반 면역치료제 및 항염증제의 경구투여를 모색하고 있습니다. 북미와 일부 유럽 국가들은 강력한 R&D 인프라와 규제 당국의 개입으로 기술 혁신을 주도하고 있습니다. 신흥국들은 비용 효율적인 제제 개발에 주목하고 의약품에 대한 접근성을 확대하기 위해 노력하고 있습니다.

경구용 단백질 및 펩티드 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다.

경구용 단백질 및 펩티드 시장의 성장은 주사 가능한 생물학적 제제를 대체할 수 있는 간편한 제제에 대한 수요 증가, 약물 안정화 기술의 발전, 만성 질환에 대한 펩티드의 치료 용도 확대 등의 요인에 기인합니다. GLP-1 유사체 및 기타 대사 치료제의 채택이 증가함에 따라 경구용 펩티드 전달 플랫폼에 대한 상업적 관심이 높아지고 있습니다.

생체 이용률 향상제, 보호 코팅, 장내 흡수 모델의 발전은 외래에서 펩티드 치료의 적용 확대를 촉진하고 있습니다. 임상 파이프라인의 확대는 환자 선호도 및 새로운 규제 당국의 승인과 함께 장기적인 시장 성장을 위한 탄탄한 기반이 되고 있습니다. 생명공학 및 전달 기술 기업과의 전략적 파트너십은 진화하는 이 분야의 혁신 속도를 더욱 가속화하고 있습니다.

부문

약물 유형(칼시토닌 약물 유형, 인슐린 약물 유형, 리나클로타이드 약물 유형, 옥트레오타이드 약물 유형, 플레카나타이드 약물 유형); 용도(뼈 질환 용도, 당뇨병 용도, 위장 및 소화 장애 용도, 호르몬 장애 용도)

조사 대상 기업 예

  • AbbVie Inc.
  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Chiasma Inc.
  • Entera Bio Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • Proxima Concepts Limited
  • Rani Therapeutics, LLC
  • Sanofi S.A.
  • Synergy Pharmaceuticals Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.26

Global Oral Proteins and Peptides Market to Reach US$2.0 Billion by 2030

The global market for Oral Proteins and Peptides estimated at US$1.3 Billion in the year 2024, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Calcitonin Drug Type, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$762.5 Million by the end of the analysis period. Growth in the Insulin Drug Type segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$351.6 Million While China is Forecast to Grow at 11.3% CAGR

The Oral Proteins and Peptides market in the U.S. is estimated at US$351.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$411.9 Million by the year 2030 trailing a CAGR of 11.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Oral Proteins and Peptides Market - Key Trends & Drivers Summarized

Why Has Oral Delivery of Proteins and Peptides Remained Technically Difficult?

Proteins and peptides are sensitive biological molecules with poor intrinsic stability in the digestive system. When administered orally, they face rapid degradation by gastric enzymes and harsh pH conditions, followed by limited intestinal absorption due to large molecular size and hydrophilicity. These barriers have historically limited oral use of therapeutic proteins, pushing most into parenteral routes. However, recent scientific progress is making oral delivery more plausible, driving new investment in peptide-based oral drug development.

The motivation behind oral delivery is strong, particularly for long-term treatments like diabetes, growth disorders, and hormonal deficiencies. Patients prefer oral therapies over injections for convenience, comfort, and reduced risk of injection-related complications. Hence, the pharmaceutical industry is actively working on approaches to stabilize peptide structures and promote mucosal transport for systemic absorption.

What Formulation Techniques Are Enabling Systemic Uptake via the GI Tract?

Several formulation strategies are under active development to enable oral delivery of peptides and proteins. Use of enteric-coated capsules and enzyme inhibitors helps protect the drug until it reaches the intestine. Absorption enhancers such as medium-chain fatty acids and bile salts are employed to loosen tight junctions in the intestinal lining, temporarily increasing permeability. Carrier systems like nanoparticles, self-emulsifying drug delivery systems (SEDDS), and lipid-based formulations are designed to improve drug solubility and stability.

Technologies such as permeation-enhancing microcontainers, mucoadhesive films, and transcellular transporters are being refined to achieve consistent and safe absorption. Structural modification of peptides, including cyclization and D-amino acid substitution, improves resistance to enzymatic cleavage without affecting biological activity. These methods are allowing more peptide drugs to achieve bioavailability levels sufficient for therapeutic effect.

Which Therapies Are Leading in Development and Where Is Innovation Concentrated?

Diabetes and metabolic disorders are the leading therapeutic segments for oral peptide development. Oral semaglutide, a GLP-1 receptor agonist for type 2 diabetes, is the most notable commercial success, marking a breakthrough in this space. Similar efforts are targeting oral formulations of insulin, parathyroid hormone, and calcitonin for osteoporosis and thyroid-related disorders.

Biopharmaceutical companies are also exploring oral delivery of peptide-based immunotherapies and anti-inflammatory agents for conditions such as rheumatoid arthritis and ulcerative colitis. North America and select European countries are leading innovation due to strong R&D infrastructure and regulatory engagement. Emerging economies are watching closely for cost-effective formulations to broaden access.

Growth in the Oral Proteins and Peptides market is driven by several factors…

Growth in the oral proteins and peptides market is driven by factors such as increasing demand for convenient alternatives to injectable biologics, progress in drug stabilization techniques, and growing therapeutic use of peptides in chronic diseases. Rising adoption of GLP-1 analogs and other metabolic treatments is fueling commercial interest in oral peptide delivery platforms.

Advancements in bioavailability enhancers, protective coatings, and intestinal absorption models are supporting wider application of peptide therapies in outpatient settings. Expansion of clinical pipelines, coupled with favorable patient preferences and emerging regulatory approvals, is creating a strong foundation for long-term market growth. Strategic partnerships between biotech firms and delivery technology companies are further accelerating the pace of innovation in this evolving field.

SCOPE OF STUDY:

The report analyzes the Oral Proteins and Peptides market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type, Plecanatide Drug Type); Application (Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application, Hormonal Disorders Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Chiasma Inc.
  • Entera Bio Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • Proxima Concepts Limited
  • Rani Therapeutics, LLC
  • Sanofi S.A.
  • Synergy Pharmaceuticals Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Oral Proteins and Peptides - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Interest in Non-Invasive Biologic Delivery Spurs Innovation in Oral Protein and Peptide Formulations
    • Advancements in Permeation Enhancers Strengthen Business Case for Gastrointestinal Absorption Technologies
    • Surge in Oral GLP-1 Receptor Agonist Development Throws the Spotlight on Diabetes and Obesity Therapies
    • Increasing Focus on Enzyme and Hormone Replacement Expands Addressable Market for Oral Biologics
    • Progress in Nanotechnology and Carrier Systems Enhances Stability and Bioavailability of Oral Peptides
    • Use of Enteric Coating and Mucoadhesive Polymers Propels Controlled Release Formulation Development
    • Rising Investment in Oral Immunotherapy Supports New Pathways for Allergy and Autoimmune Treatment
    • Expansion of Biopharma Pipelines in Peptides Drives Demand for Alternative Drug Delivery Routes
    • Growing Application in Oncology and Rare Diseases Opens High-Value Market Segments for Oral Peptides
    • Technological Advances in Oral Nanocarriers Enhance Gastrointestinal Uptake and Therapeutic Impact
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oral Proteins and Peptides Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oral Proteins and Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Calcitonin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Calcitonin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Calcitonin Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Insulin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Insulin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Insulin Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Linaclotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Linaclotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Linaclotide Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Octreotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Octreotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Octreotide Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Plecanatide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Plecanatide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Plecanatide Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Bone Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Bone Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Bone Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Diabetes Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Gastric & Digestive Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Gastric & Digestive Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Gastric & Digestive Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hormonal Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hormonal Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Hormonal Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • JAPAN
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • CHINA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: China 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • EUROPE
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Oral Proteins and Peptides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • FRANCE
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: France 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • GERMANY
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Oral Proteins and Peptides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • INDIA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: India 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Oral Proteins and Peptides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Oral Proteins and Peptides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • AFRICA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제